| Name | Title | Contact Details |
|---|
The Louis D. Brandeis Center, Inc. (LDB) is an independent, non-partisan institution for public interest advocacy, research and education. The Centers mission is to advance the civil and human rights of the Jewish people and to promote justice for all.
Cimplifi is a leading integrated legal services provider, leveraging technology and expertise to simplify the experience of eDiscovery and contract analytics for law firms and legal departments. Our client-centric ecosystem and experience offer a curated portfolio of technology-enabled solutions that integrates proprietary tools and automated workflows with market-leading software to deliver an easy-to-use, end-to-end system that streamlines processes, unifies reporting, and empowers users. For more than two decades, clients have relied on our expertise and ingenuity to solve complex challenges, bring innovative solutions, and deliver intelligence and insight to help them manage risk, control costs, and get more done, more effectively and with far less effort and stress. Cimplifi is ISO 27001 certified and is a division of System One. Learn more at www.cimplifi.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Manufacturing and sale of industrial precision balls, rollers, cages and sheet metal parts used for bearing and other applications. Manufacturing and sale of ball screws, and large scale blowers.